Literature DB >> 23488881

Cancer risk in Japanese Crohn's disease patients: investigation of the standardized incidence ratio.

Yutaka Yano1, Toshiyuki Matsui, Fumihito Hirai, Yuki Okado, Yuho Sato, Kozue Tsurumi, Satoshi Ishikawa, Tsuyoshi Beppu, Akihiro Koga, Naoyuki Yoshizawa, Daijiro Higashi, Kitaro Futami.   

Abstract

BACKGROUND AND AIM: There have been very few reported investigations on the standardized incidence ratio (SIR) of intestinal cancer and all cancers other than intestinal cancer with Crohn's disease (CD) by organ in Japan. This study examined the risk of developing cancer (i.e. SIR) that occurs in association with CD.
METHODS: The subjects were 770 CD patients managed at our hospital department, which specializes in inflammatory bowel disease, during the approximately 25 years from July 1985 to August 2010. The number of expected cancer patients in a healthy population matched for sex and age with the CD patients in our hospital was then calculated. The relative risk, or SIR, was also calculated.
RESULTS: The total observation period was 10,552 person-years, during which 19 cases (2.5%) of cancer were discovered in 770 subjects. The cancer cases included nine cases of colorectal cancer (CRC), one case of small bowel cancer, one case of stomach cancer, three cases of acute myeloid leukemia, two cases of endometrial cancer, one case of lung cancer, one case of skin cancer, and one case of thyroid cancer. The SIR for cancers in Japan in 2003 was 0.87 (95% confidence interval [CI] 0.52-1.35) for all cancers, 2.79 (95% CI 1.28-5.29) for CRC, and 6.94 (95% CI 1.43-20.3) for leukemia.
CONCLUSIONS: Among the cancers in CD patients in our hospital, no significant difference was seen in the risk for all cancers in comparison with the standard population. However, the risks for CRC and leukemia were significantly higher than in the standard population.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Crohn's disease; Japanese; anti-TNF-α; cancer; standardized incidence ratio (SIR)

Mesh:

Year:  2013        PMID: 23488881     DOI: 10.1111/jgh.12189

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  11 in total

Review 1.  Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature.

Authors:  Farhan Mohammad; Abhirami Vivekanandarajah; Housam Haddad; Christopher M Shutty; Matthew T Hurford; Qun Dai
Journal:  BMJ Case Rep       Date:  2014-05-19

2.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

3.  Hematologic malignancies in the Japanese patients with inflammatory bowel disease.

Authors:  Norimasa Fukata; Kazuichi Okazaki; Mika Omiya; Mitsunobu Matsushita; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2013-08-19       Impact factor: 7.527

Review 4.  Intestinal stricture in Crohn's disease.

Authors:  Chen-Wang Chang; Jau-Min Wong; Chien-Chih Tung; I-Lun Shih; Horng-Yuan Wang; Shu-Chen Wei
Journal:  Intest Res       Date:  2015-01-29

Review 5.  Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis.

Authors:  Lihong Cao
Journal:  World J Surg Oncol       Date:  2018-09-10       Impact factor: 2.754

6.  Crohn's disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan.

Authors:  Shigeyoshi Yasukawa; Toshiyuki Matsui; Yutaka Yano; Yuho Sato; Yasumichi Takada; Masahiro Kishi; Yoichiro Ono; Noritaka Takatsu; Takashi Nagahama; Takashi Hisabe; Fumihito Hirai; Kenshi Yao; Toshiharu Ueki; Daijiro Higashi; Kitaro Futami; Suketo Sou; Toshihiro Sakurai; Tsuneyoshi Yao; Hiroshi Tanabe; Akinori Iwashita; Masakazu Washio
Journal:  J Gastroenterol       Date:  2018-06-09       Impact factor: 7.527

Review 7.  How Does the Epidemiology of Inflammatory Bowel Disease Differ between East and West? A Korean Perspective.

Authors:  Suk-Kyun Yang
Journal:  Inflamm Intest Dis       Date:  2017-01-14

Review 8.  Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Chelle L Wheat; Kindra Clark-Snustad; Beth Devine; David Grembowski; Timothy A Thornton; Cynthia W Ko
Journal:  Gastroenterol Res Pract       Date:  2016-05-16       Impact factor: 2.260

Review 9.  Concomitant Thyroid Disorders and Inflammatory Bowel Disease: A Literature Review.

Authors:  Toru Shizuma
Journal:  Biomed Res Int       Date:  2016-03-03       Impact factor: 3.411

10.  Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.

Authors:  Brigida Barberio; Fabiana Zingone; Renata D'Incà; Laura Rovigo; Lorenzo Bertani; Giorgia Bodini; Matteo Ghisa; Alessandro Gubbiotti; Davide Massimi; Greta Lorenzon; Edoardo Vincenzo Savarino
Journal:  Clin Transl Gastroenterol       Date:  2020-05       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.